Rotavirus infection is the leading cause of severe gastroenteritis among infants and young children worldwide. Before the introduction of rotavirus vaccine in the United States in 2006, rotavirus infection caused significant morbidity among U.S. children, with an estimated 55,000-70,000 hospitalizations and 410,000 clinic visits annually. The disease showed a characteristic winter-spring season...

OBJECTIVES Rotavirus vaccination has been reimbursed in Belgium since November 2006 with a high uptake (>85%). Economic analyses of the vaccine have been reported, including estimates of indirect cost gain related to the reduction in work absenteeism. The objective of this study was to evaluate the latter parameter using real-life data. DESIGN AND SETTING A simple model estimated the reductio...

OBJECTIVES To determine the burden and molecular epidemiology of rotavirus gastroenteritis in children hospitalized with severe acute watery diarrhea in Pakistan prior to introduction of rotavirus vaccine. METHODS A cross-sectional study was carried out over a period of two years from 2006 - 2008 at five sentinel hospitals in the cities of Karachi, Lahore, Rawalpindi, and Peshawar. Stool samp...

The decision to develop rotavirus vaccines was predicated on the extensive burden of rotavirus disease among children worldwide. US reports on nationwide hospitalizations (1979-1992) and deaths (1968-1991) due to diarrhea and weekly reports of rotavirus infection by 74 laboratories were reviewed to estimate the burden of rotavirus disease, identify epidemiologic trends, and consider methods for...

BACKGROUND Rotavirus, predominantly of group A, is a major cause of severe diarrhoea worldwide, with the greatest burden falling on young children living in less-developed countries. Vaccines directed against this virus have shown promise in recent trials, and are undergoing effectiveness evaluation in sub-Saharan Africa. In this region limited childhood data are available on the incidence and ...

The successful development and implementation of rotavirus vaccines will have a significant impact on rotavirus-induced gastroenteritis in children worldwide. However, this introduction will increase the immune pressure against wild-type rotavirus strains circulating in the community, altering the forces and balances that drive rotavirus evolution. There is concern that antigenically distinct n...

The recent approval of a rotavirus vaccine in Mexico motivates this study on the potential impact of the use of such a vaccine on rotavirus prevention and control. An age-structured model that describes the rotavirus transmission dynamics of infections is introduced. Conditions that guarantee the local and global stability analysis of the disease-free steady state distribution as well as the ex...

By the age of five years, between 1 in 40 and 1 in 77 children in Europe and the USA will have been hospitalised for rotavirus diarrhoea. Although health care and economic costs of the illness are high, mortality in developed countries is very low. In contrast with the developing world, and despite considerable efforts to educate carers in simple oral rehydration therapy, it is estimated that 6...

The global health community is beginning to gain an understanding of the global burden of norovirus-associated disease, which appears to have significant burden in both developed- and developing-country populations. Of particular importance is the growing recognition of norovirus as a leading cause of gastroenteritis and diarrhea in countries where rotavirus vaccine has been introduced. While n...